Literature DB >> 19430663

Ocular toxoplasmosis: the influence of patient age.

Gary N Holland1.   

Abstract

The influence of patient age on various features of ocular toxoplasmosis has been a subject of study for many years. The age at which Toxoplasma gondii infection occurs in different populations is related to socioeconomic factors and studies suggest that ocular toxoplasmosis is a more severe disease at the extremes of age. The prevalence of ocular involvement is markedly different between individuals with congenital and those with post-natally acquired infections. Even among those with post-natally acquired infections, age influences the risk and timing of ocular involvement. The severity of toxoplasmic retinochoroiditis (in terms of lesion size, location and associated inflammation) is also affected by patient age at the time of initial infection or recurrence. The risk of recurrent toxoplasmic retinochoroiditis is influenced by age at the time of initial infection and age at most recent episode of active disease. Understanding of relationships between ocular toxoplasmosis and patient age is incomplete; evidence has often been indirect and in some cases conflicting. The influence of patient age on ocular toxoplasmosis should be studied in a systematic manner to provide a better understanding of disease mechanisms and to provide clinical information that can used to establish better strategies for disease treatment and prevention.

Entities:  

Mesh:

Year:  2009        PMID: 19430663     DOI: 10.1590/s0074-02762009000200031

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  22 in total

1.  Toxoplasmosis: new challenges for an old disease.

Authors:  B Bodaghi; V Touitou; C Fardeau; L Paris; P LeHoang
Journal:  Eye (Lond)       Date:  2012-01-06       Impact factor: 3.775

2.  CXCL10 is required to maintain T-cell populations and to control parasite replication during chronic ocular toxoplasmosis.

Authors:  Kazumi Norose; Akitoshi Kikumura; Andrew D Luster; Christopher A Hunter; Tajie H Harris
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-01-21       Impact factor: 4.799

3.  Clinical pattern of ocular toxoplasmosis treated in a referral centre in Serbia.

Authors:  D Kovačević-Pavićević; A Radosavljević; A Ilić; I Kovačević; O Djurković-Djaković
Journal:  Eye (Lond)       Date:  2012-02-24       Impact factor: 3.775

4.  Toxoplasmosis.

Authors:  Sandra K Halonen; Louis M Weiss
Journal:  Handb Clin Neurol       Date:  2013

5.  Ocular toxoplasmosis in Iran: 40 cases analysis.

Authors:  Seidali Tabatabaei; Mohammad Soleimani; Alireza Foroutan; Mehdinili Ahmadabadi; Reza Zarei; Nilofar Piri; Arzhang Gordiz
Journal:  Int J Ophthalmol       Date:  2011-04-18       Impact factor: 1.779

Review 6.  Importance of nonenteric protozoan infections in immunocompromised people.

Authors:  J L N Barratt; J Harkness; D Marriott; J T Ellis; D Stark
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

Review 7.  Toxoplasma gondii in South America: a differentiated pattern of spread, population structure and clinical manifestations.

Authors:  Gabriella de Lima Bessa; Ricardo Wagner de Almeida Vitor; Erica Dos Santos Martins-Duarte
Journal:  Parasitol Res       Date:  2021-08-14       Impact factor: 2.289

8.  Toxoplasma gondii seroprevalence in Mali.

Authors:  Dinkorma T Ouologuem; Abdoulaye A Djimdé; Nouhoum Diallo; Ogobara K Doumbo; David S Roos
Journal:  J Parasitol       Date:  2012-08-27       Impact factor: 1.276

9.  Assessment of ocular toxoplasmosis patients reported at a tertiary center in the northeast of Iran.

Authors:  Seyedeh Maryam Hosseini; Elham Moghaddas; Karim Sharifi; Malihe Dadgar Moghaddam; Seyed Aliakbar Shamsian
Journal:  Int Ophthalmol       Date:  2018-01-15       Impact factor: 2.031

10.  Azithromycin versus Sulfadiazine and Pyrimethamine for non-vision-threatening toxoplasmic retinochoroiditis: a pilot study.

Authors:  Konstantinos Balaskas; Jean Vaudaux; Noémie Boillat-Blanco; Yan Guex-Crosier
Journal:  Med Sci Monit       Date:  2012-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.